Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing engineered bacterial therapies for gastrointestinal and liver diseases. The company’s proprietary platform leverages synthetic biology to engineer nonpathogenic microbial strains capable of producing therapeutic molecules directly at sites of disease within the gut. By combining microbiome science with precision genetic engineering, Eupraxia aims to address conditions that have proven difficult to treat with conventional small molecules or biologics.

The company’s pipeline comprises multiple lead programs in early clinical and preclinical development. These candidates are designed to modulate immune and metabolic pathways through localized delivery of bioactive proteins and peptides. Eupraxia’s approach seeks to reduce systemic exposure and off-target effects by confining therapeutic activity to the gastrointestinal tract. Key areas of investigation include inflammatory bowel diseases, cholestatic liver disorders and other chronic GI conditions with high unmet medical need.

Headquartered in Dallas, Texas, Eupraxia Pharmaceuticals went public on the Nasdaq Global Market under the ticker symbol EPRX. The company is led by a team of experienced biopharmaceutical executives and scientists with expertise in synthetic biology, microbiome research and clinical development. Through strategic partnerships and a growing pipeline, Eupraxia aims to advance novel microbial therapies that could transform the treatment landscape for digestive and liver diseases.

Key Stats

• Today's Range: $5.26 to $5.38
• 50-Day Range: $3.79 to $5.84
• 52-Week Range: $2.20 to $6.20
• Volume: 4,195 shs
• Average Volume: 13,482 shs
• Market Capitalization: $190.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

EPRX Stock Analysis - Frequently Asked Questions

How have EPRX shares performed this year?

Eupraxia Pharmaceuticals' stock was trading at $3.17 at the beginning of the year. Since then, EPRX stock has increased by 66.9% and is now trading at $5.29.

How were Eupraxia Pharmaceuticals' earnings last quarter?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released its earnings results on Tuesday, May, 6th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02.

How do I buy shares of Eupraxia Pharmaceuticals?

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eupraxia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Cos (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPRX
• Previous Symbol: NASDAQ:EPRX
• CIK: 1581178
• Web: www.eupraxiapharma.com
• Phone: 250-590-3968
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eupraxia Pharmaceuticals: $11.00
• High Price Target: $12.00
• Low Price Target: $9.00
• Potential Upside/Downside: +107.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -367.73%
• Return on Assets: -112.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.10
• Quick Ratio: 11.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,960,000
• Free Float: N/A
• Market Cap: $190.23 million
• Optionable: N/A
• Beta: 1.55